D-0258-2025 Class III
FDA drug recall D-0258-2025 was initiated by Kowa Pharmaceuticals America on Feb 24, 2025 and is designated Class III. Reason for recall: Presence of foreign tablets/capsules Affected quantity: 5,328 Bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 19, 2025
- Initiation Date
- Feb 24, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 5,328 Bottles
Product description
Livalo (pitavatstatin) tablets, 4 mg, 90-count bottles, Rx only, Manufactured by: Patheon, Inc. Cincinnati, OH 45237 USA or by Kowa Company, Ltd, Nagoya, 462-0024 Japan, Marketed by Kowa Pharmaceuticals: Kowa Pharmaceuticals America Inc., Montgomery, AL 36117 USA NDC 66869-404-90 HDPE Bottle, congregated into a shrink wrapped 6-pack further congregated into 24 6-packs in a cardboard case
Reason for recall
Presence of foreign tablets/capsules
Distribution pattern
PA, OH, and TX
Code information
Lot#: 3231300, Exp 8/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0258-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026